Effect of enzyme inhibitors on cell proliferation and migration of MDA-MB-231 cells.

MDA-MB-231 tumor cells treated with either vehicle or roziglitazone (Ros), troglitazone (Trog), Triasin C (TriC), zileuton (Zil), AA861, ibuprofen (Ibu), etoricoxib (Eto) as ACSL4, LOX-5 and COX-2 inhibitors, respectively, alone or in combination as indicated were incubated during 12 or 96 h and cell migration and proliferation assayed as described in Materials and Methods.Doses employed were: 25 µM for Ros and Trog; 100 µM and 5 µM for Zil and AA861 respectively; 100 µM and 0.01 µM for Ibu and Eto respectively and 5 µM for TriC.Data represent the mean ± SD of 2 or 3 independent experiments for cell migration and proliferation, respectively, performed in quintuplicate. * P

以溶剂对照（vehicle）或分别作为酰基辅酶A合成酶长链家族成员4（ACSL4）、5-脂氧合酶（LOX-5）与环氧合酶2（COX-2）抑制剂的罗格列酮（Roziglitazone, Ros）、曲格列酮（Troglitazone, Trog）、Triasin C（TriC）、齐留通（Zileuton, Zil）、AA861、布洛芬（Ibuprofen, Ibu）、依托考昔（Etoricoxib, Eto）单独或按指示联合处理MDA-MB-231肿瘤细胞，将细胞孵育12或96小时后，按照材料与方法所述检测细胞迁移与增殖能力。所用给药剂量如下：罗格列酮与曲格列酮均为25 μM；齐留通与AA861分别为100 μM和5 μM；布洛芬与依托考昔分别为100 μM和0.01 μM；Triasin C为5 μM。实验数据分别为细胞迁移的2次独立重复实验、增殖的3次独立重复实验的平均值±标准差，所有实验均设置5个复孔，*P